

	1994				F/ M	15-≥45				108/250	47.2/15.2
	1991, 1992 and 1994	Individuals at low risk of HIV infection	Western blot		F+ M	15-≥45				766	13.6
					F/ M	15-≥45				287/479	17.1/11.5
Tanzania, Dar es Salaam [8]	Pre- 2002	STI clinic attendees with genital ulcers	HSV-2-specific branched synthetic oligopeptide assay		F+ M	Mean 29.7; median 28				70	78.6
					F/ M	Mean 29.7; median 28				19/51	84.2/76.5
Tanzania, Moshi [9]	2000	Bar and hotel workers	Type-specific EIA (ELISA; Meridian Diagnostics)		F+ M	29.5 (16-66)				515	43.5
					F/ M	29.5 (16-66)				309/206	53.1/29.1
					F	16-20				42	33.3
						21-25				113	45.1
						26-30				71	59.2
						31-35				32	65.6
						≥36				51	70.6
					M	16-25				63	14.3
						26-30				49	26.5
						31-35				34	32.4
						≥36				60	45.0
Tanzania, Moshi [10]	1999	Primary health clinic attendees	Type-specific ELISA (Gull)		F	27 (16-46)				378	39.4
						15-19				35	22.9
						20-29				234	36.8
						30-49				113	48.7
Uganda [5]	Pre- 2002	HIV-negative family planning clinic attendees	Western blot		F	18-35				176	61.9
Uganda, Masaka [11]	1994- 2000	General population	Type-specific EIA		F+ M	13-29				7032	27.7
					F/ M	13-29				3818/32 14	37.7/15.8

Zimbabwe, Harare [5]	Pre-2002	HIV-negative STI clinic attendees	Western blot	F	18-35			173	66.5
Zimbabwe, Harare [12]	1999-2000	Primary health clinic attendees	Type-specific ELISA (Gull)	F	25 (6-49)			389	42.2
					<20			44	27.3
					20-25			169	36.7
					>26			180	50.0
Central and South America									
Jamaica, Kingston [13]	1993-1997	CIN-1 patients	Type-specific ELISA (Focus Technologies)	F	31.2			201	60.9
Mexico, Chiapas state, Soconusco region [14]	1998	Commercial sex workers	Western blot	F	Mean 25.6; median 23.7 (15-47)			460	85.7
Mexico, Morelos state [15]	2000	Sexually-active students	Western blot	F+ M	≤15-≥18			898	5.7
				E/ M	17.5/18.1 (11-24)			381/517	7.9/4.1
				F+ M	≤15			204	7.4
					16-17			205	4.9
					≥18			489	5.3
				F	≤15			91	9.9
					16-17			98	6.1
					≥18			192	7.8
				M	≤15			113	5.3
					16-17			107	3.7
					≥18			297	3.7
Peru [17]	Pre-2002	Hospital-based controls in a study of cervical cancer matched by age	Western blot	F	52 (28-68)			171	35.7
South America [18]	Pre-2002	Village children	Type-specific immunodot enzyme assay	F+ M	1-13			201	71
					0-3			23	29

					Not under prenatal care 15-16	75	32.0	75	0.0
					Not under prenatal care 17-18	90	28.9	90	5.6
					Not under prenatal care 19-20	89	43.8	89	2.2
					Not under prenatal care 21-22	95	53.7	95	4.2
					Not under prenatal care 23-24	92	57.5	92	1.1
					Not under prenatal care 25-29	48	43.8	48	4.2
					Not under prenatal care 30-34	52	71.2	52	13.5
					Not under prenatal care 35-39	44	75.0	44	15.9
					Not under prenatal care 40-44	53	88.7	53	18.9
				M	15-16	104	26.9	104	3.8
					17-18	126	27.0	126	3.2
					19-20	132	37.1	132	6.1
					21-22	135	28.1	135	1.5
					23-24	141	43.3	141	0.7
					25-29	89	44.9	89	6.7
					30-34	92	63.0	92	9.8
					35-39	85	55.3	85	5.9
					40-44	75	54.7	75	21.3
USA, various cities [24]	1993- 1994, 1995- 1997	HIV-positive homosexuals	Western blot	M	30.5 (19-54)	116	64.7	116	41.4
		HIV-negative homosexuals	Western blot	M	31 (18-61)	342	58.8	342	31.0
USA, four cities [25]	1993- 1999	HIV-positive individuals	Type-specific immunoblot	F	16-55	844	74.5	844	67.7
					16-25	67	79.1	67	56.7
					26-30	152	69.7	152	64.5
					31-35	251	74.9	251	66.5
					36-40	196	74.0	196	69.4
					41-45	120	81.7	120	72.5
					46-55	58	67.2	58	77.6

		Demographically-matched HIV-negative individuals	Type-specific immunoblot	F	16-55	423	74.5	423	56.7
					16-25	48	62.5	48	39.6
					26-30	84	77.4	84	51.2
					31-35	98	73.5	98	56.1
					36-40	106	82.1	106	61.3
					41-45	53	67.9	53	62.3
					46-55	34	73.5	34	73.5
USA, Baltimore, Denver, Long Beach, Newark and San Francisco [26]	1993-1996	HIV-negative STI clinic attendees	Type-specific strip immunoblot (Chiron)	F+ M	25 (14-76)	4128	70.7	4128	40.8
				F+ M	25 (14-76)	1780/2348			52.0/32.4
				F+ M	14-19	724			23.6
					20-24	1198			34.3
					25-29	802			42.5
					30-39	977			49.9
					≥40	427			64.6
USA, California, San Francisco [30]	1997-2000	HIV test takers	Type-specific ELISA (Focus Technologies)	F/ M	32 (18-71)	143/844			23.5
				F	32 (18-71)	136			28.7
				M	Heterosexual	92			13.0
					Homosexual	752			24.1
				F+ M	≤29	294			11.2
					30-39	449			21.2
					≥40	239			42.7
USA, Pennsylvania, Pittsburgh [35]	1998-2000	Women seeking medical care requiring a gynaecologic examination	Type-specific ELISA (Focus Technologies)	F	18-30	1207			24.9
					18-20	553			15.0
					21-25	466			29.0
					26-30	188			44.1
USA, Texas, Lubbock and Houston [37]	1998-1999	Drug users	Type-specific assay	F/ M	<17-64	113/294			44.4

USA, Washington, Seattle and Oregon, Portland [39]	Pre-2002	Individuals with a history of genital herpes.	Western blot	M	35 (21-73)	68	44.1	68	92.6
USA, Washington, Seattle [40]	Pre-2002	Individuals with recurrent genital HSV-2 infection	Western blot	F/ M	33.5 (20-73)	51/33	38.1		
USA, Washington, Seattle and Canada, British Columbia, Vancouver [41]	1993-2000	Pregnant women with a history of genital herpes	Type-specific assay	F	31/30 (17-45)	107	43.9	107	95.3
Asia/Australia									
Australia, Melbourne [50]	1995-1996	Individuals with no history of genital herpes and with a heterosexual partner with genital herpes due to HSV-2	Western blot	F+ M	18-45	337	68.5	337	33.2
				F/ M	32/34	160/177	75.0/62.7	160/177	42.5/24.9
				F+ M	18-25	44	63.6	44	29.5
					26-30	88	59.1	88	39.8
					31-35	87	71.3	87	28.7
					36-40	64	75.0	64	40.6
					41-45	54	75.9	54	24.1
Bangladesh, Dhaka [53]	1998-1999	Truck drivers and their helpers	Type-specific ELISA (Diasorin)	M	26.8			387	25.8
					15-20			100	31
					21-26			114	21
					27-32			96	23
					≥33			77	30
India, Pune [54]	1993-2000	HIV-negative STI clinic attendees	Type-specific EIA (Focus Technologies)	F/ M	<20-≥30			463/226 9	43.0
				F	With STI: <20-≥30			271	50.9
					CSW: <20-≥30			192	89.1
				M	With STI: <20-≥30			2260	38.1

	2002	study of cervical cancer							
Thailand, Lampang and Songkla provinces [59]	1997-1998; 1999-2000	General population	Type-specific ELISA (Focus Technologies)	F	<25-≥65			1703	30.8
Europe/Middle East									
Denmark [60]	Pre-2002	Prisoners	Type-specific assay (Gull)	M	30			328	17.7
		Drug users	Type-specific assay (Gull)	F/ M	37			48/89	32.8
France [64]	1996	General population	Type-specific EIA (Gull)	F+ M	35->55	4412	67	4412	17.2
				F	35->55		65.0		17.9
				M	45->55		66.4		13.7
				F	35-40		58.3		15.7
					40-45		59.2		18.8
					45-50		66.4		18.1
					50-55		68.5		17.0
					>55		74.7		19.5
				M	45-50		64.5		12.5
					50-55		64.6		14.2
					>55		70.9		15.0
Italy, various sites [68]	1983-1995	AIDS-free HIV-positive individuals	Type-specific ELISA (Gull/Meridian)	F+ M	28 (16-66)			380	33.2
				F/ M	28 (16-66)			86/294	17.4/37.8
Italy, Milan [69]	1997-1998	HIV-negative STI clinic attendees	Type-specific ELISA (Meridian Diagnostics)	F+ M	31 (16-78)			776	29.5
				F/ M	31 (16-78)			229/547	27.5/30.3
				F+ M	<40			594	23.7
					≥40			182	48.4
				F	<25			70	15.7

